Nanostructured SBA-15 silica as an adjuvant in immunizations with hepatitis B vaccine.

OBJECTIVE To evaluate the applicability of SBA-15 silica as an adjuvant in immunizations with purified particles of the viral protein HBsAg, the main component of hepatitis B vaccine, Butang®, produced by Instituto Butantan. METHODS BALB/c mice orally or subcutaneously received 0.5 μg of HBsAg adsorbed/encapsulated to SBA-15 or adsorbed to Al(OH)3. To assess the secondary immune response, a subcutaneous booster was administered 30 days after the first immunization. Individual serum and fecal samples of each group were periodically collected for specific antibody titration by ELISA. RESULTS Analysis of secretory IgA showed that mice orally primed with HBsAg on SBA-15 had increased levels of specific antibodies in primary and secondary immune responses. Specific serum IgA and IgG titers in HBsAg:SBA-15-orally immunized mice reached higher levels after the booster, demonstrating the effectiveness of oral vaccination with the use of silica. All immunized groups showed higher IgG1 levels. CONCLUSION Our results clearly indicate the promising use of SBA-15 as an adjuvant, especially in oral immunizations.

[1]  D. Tambourgi,et al.  Immunological parameters related to the adjuvant effect of the ordered mesoporous silica SBA-15. , 2010, Vaccine.

[2]  K. Sherman,et al.  Occult Hepatitis B: Clinical Implications and Treatment Decisions , 2010, Digestive Diseases and Sciences.

[3]  Y. Lobaina,et al.  The effect of the parenteral route of administration on the immune response to simultaneous nasal and parenteral immunizations using a new HBV therapeutic vaccine candidate. , 2010, Viral immunology.

[4]  W. Gerlich,et al.  Occult Hepatitis B Virus Infection: Detection and Significance , 2010, Digestive Diseases.

[5]  Karina Scaramuzzi,et al.  Uma história contada no futuro: complexo imunogênico constituído por antígenos vacinais adsorvidos/encapsulados em sílica mesoporosa nanoestruturada , 2009 .

[6]  M. Fantini,et al.  A story told in future: complex incorporated by antigens immunogenic vaccine adsorbed/encapsulated mesoporous silica nanostructured , 2009 .

[7]  Shraddha S. Nigavekar,et al.  Pre-Clinical Evaluation of a Novel Nanoemulsion-Based Hepatitis B Mucosal Vaccine , 2008, PloS one.

[8]  V. Bruss.  Hepatitis B virus morphogenesis. , 2007, World journal of gastroenterology.

[9]  D. Glebe.  Recent advances in hepatitis B virus research: a German point of view. , 2007, World journal of gastroenterology.

[10]  M. Jaroniec,et al.  Ordered mesoporous silica SBA-15: a new effective adjuvant to induce antibody response. , 2006, Small.

[11]  J. Brewer.  (How) do aluminium adjuvants work? , 2006, Immunology letters.

[12]  J. Kraehenbuhl,et al.  Keeping the Gut Microflora at Bay , 2004, Science.

[13]  M. Jaroniec,et al.  Toward the Synthesis of Extra-Large-Pore MCM-41 Analogues , 2001 .

[14]  N. Tornieporth,et al.  A prophylactic hepatitis B vaccine with a novel adjuvant system. , 2001, Vaccine.

[15]  Raw,et al.  Safety and immunogenicity of hepatitis B vaccine ButaNG in adults , 1999, Revista do Instituto de Medicina Tropical de Sao Paulo.

[16]  E. S. Baekkevold,et al.  Regional specialization in the mucosal immune system: what happens in the microcompartments? , 1999, Immunology today.

[17]  Smith,et al.  Physiological considerations in the design of particulate dosage forms for oral vaccine delivery. , 1998, Advanced drug delivery reviews.

[18]  Fredrickson,et al.  Triblock copolymer syntheses of mesoporous silica with periodic 50 to 300 angstrom pores , 1998, Science.

[19]  Geoffrey A. Ozin,et al.  Morphogenesis of shapes and surface patterns in mesoporous silica , 1997, Nature.

[20]  J. Cox,et al.  Adjuvants--a classification and review of their modes of action. , 1997, Vaccine.

[21]  B. Hirst,et al.  Targeting to intestinal M cells. , 1996, Journal of anatomy.

[22]  G. Calandra,et al.  Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. , 1996, Vaccine.

[23]  W. Shalaby.  Development of oral vaccines to stimulate mucosal and systemic immunity: barriers and novel strategies. , 1995, Clinical immunology and immunopathology.

[24]  H. Weiner.  Oral tolerance. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. S. Beck,et al.  Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism , 1992, Nature.

[26]  A. Giles,et al.  Guidelines for the use of Animals in Biomedical Research , 1987, Thrombosis and Haemostasis.